Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy

被引：0
|
作者：
Takashio, S. [1 ]
Morioka, M. [1 ]
Fujiyama, A. [1 ]
Oike, F. [1 ]
Hanatani, S. [1 ]
Usuku, H. [1 ]
Yamamoto, E. [1 ]
Matsushita, K. [1 ]
Tsujita, K. [1 ]
机构：
[1] Kumamoto Univ Hosp, Kumamoto, Japan
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：964 / 964
页数：1
相关论文
共 50 条
  • [1] Tafamidis in Transthyretin Amyloid Cardiomyopathy Effects on Transthyretin Stabilization and Clinical Outcomes
    Maurer, Mathew S.
    Grogan, Donna R.
    Judge, Daniel P.
    Mundayat, Rajiv
    Packman, Jeff
    Lombardo, Ilise
    Quyyumi, Arshed A.
    Aarts, Janske
    Falk, Rodney H.
    CIRCULATION-HEART FAILURE, 2015, 8 (03) : 519 - 526
  • [2] Tafamidis Stabilizes Transthyretin and Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy
    Falk, Rodney
    Maurer, Matthew
    Fedson, Savitri
    Judge, Daniel
    Zeldenrust, Steven
    Quyyumi, Arshed
    Pano, Arian
    Packman, Jeff
    Grogan, Donna
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (08) : S56 - S56
  • [3] Tafamidis for the treatment of transthyretin amyloidosis
    Lorenzini, Massimiliano
    Elliott, Perry M.
    FUTURE CARDIOLOGY, 2019, 15 (02) : 53 - 61
  • [4] EXPERIENCE WITH TAFAMIDIS IN A PATIENT WITH TRANSTHYRETIN AMYLOIDOSIS
    Nasonova, S. N.
    Zhirov, I., V
    Magomedov, M. M.
    Saidova, M. A.
    Osmolovskaya, Y. F.
    Tereshchenko, S. N.
    KARDIOLOGIYA, 2020, 60 (03) : 155 - 160
  • [5] Overview of Patient Demographics and Clinical Characteristics in THAOS - The Transthyretin Amyloidosis Outcomes Survey
    Cardoso, Marcio
    Coelho, Teresa
    Mundayat, Rajiv
    NEUROLOGY, 2013, 80
  • [6] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Benjamin Li
    Jose Alvir
    Michelle Stewart
    Cardiology and Therapy, 2020, 9 : 535 - 540
  • [7] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Li, Benjamin
    Alvir, Jose
    Stewart, Michelle
    CARDIOLOGY AND THERAPY, 2020, 9 (02) : 535 - 540
  • [8] Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
    Coelho T.
    Merlini G.
    Bulawa C.E.
    Fleming J.A.
    Judge D.P.
    Kelly J.W.
    Maurer M.S.
    Planté-Bordeneuve V.
    Labaudinière R.
    Mundayat R.
    Riley S.
    Lombardo I.
    Huertas P.
    Neurology and Therapy, 2016, 5 (1) : 1 - 25
  • [9] Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
    Merlini, Giampaolo
    Plante-Bordeneuve, Violaine
    Judge, Daniel P.
    Schmidt, Hartmut
    Obici, Laura
    Perlini, Stefano
    Packman, Jeff
    Tripp, Tara
    Grogan, Donna R.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2013, 6 (06) : 1011 - 1020
  • [10] Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
    Giampaolo Merlini
    Violaine Planté-Bordeneuve
    Daniel P. Judge
    Hartmut Schmidt
    Laura Obici
    Stefano Perlini
    Jeff Packman
    Tara Tripp
    Donna R. Grogan
    Journal of Cardiovascular Translational Research, 2013, 6 : 1011 - 1020
12345